Parataxis Holdings LLC has entered into a definitive agreement to acquire a controlling interest in South Korean biotech company Bridge Biotherapeutics, Inc. (KOSDAQ: 288330) for KRW 25 billion ($18.3 million), …
wikdaily 2025. Designed and Developed by Pro